← Database
M&A

IMANEO

Acquired by

PARQUEST CAPITAL

FRANCE Health Providers REV [1m EUR - 100m EUR] 06/2023

Target

IMANEO

Acquirer

PARQUEST CAPITAL

Context

Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector. This strategic operation facilitates the merger of three independent radiology practices into a single unified platform. The associate radiologists, who were already shareholders in their respective legacy firms, reinvested significantly to retain nearly 50% of the new group's capital. The investment strategy is focused on structuring the newly created entity's management and operations to allow medical staff to focus on clinical practice while providing the financial resources for aggressive organic and external growth. A unitranche debt facility, including dedicated capital expenditure lines, was secured to fund innovation in medical technology and the acquisition of additional radiology practices across the region.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Established in 2023 through the strategic merger of three prominent medical imaging entities based in Montpellier (CRP, Imacam, and I-Seris), Imaneo is a major regional player in the Occitanie healthcare market. The group provides comprehensive diagnostic imaging services through a collaborative network of specialized clinics. With a team of 70 associate radiologists and approximately 350 employees, the organization focuses on delivering high-quality medical care while leveraging shared resources to invest in technological advancements. The group is structured as a unified platform designed to integrate modern tools, including artificial intelligence solutions for diagnostics, and to attract new medical talent. By consolidating local expertise, the entity serves as a medical-led platform capable of addressing the growing demand for specialized outpatient care in southern France.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2022
LOGIN
LOGIN
LOGIN
2021
LOGIN
LOGIN
LOGIN

Other operations with IMANEO

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.